doi: 10.1136/bmj.b217.
Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine
- PMID: 19155260
- DOI: 10.1136/bmj.b217
Item in Clipboard
Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine
BMJ.
.
No abstract available
Similar articles
-
AstraZeneca pays $520m fine for off label marketing.BMJ. 2010 Apr 29;340:c2380. doi: 10.1136/bmj.c2380. BMJ. 2010. PMID: 20430836 No abstract available.
-
Merck pays $1bn penalty in relation to promotion of rofecoxib.BMJ. 2011 Nov 28;343:d7702. doi: 10.1136/bmj.d7702. BMJ. 2011. PMID: 22123916 No abstract available.
-
Pharmaceuticals and medical devices: FDA oversight.Issue Brief Health Policy Track Serv. 2013 Dec 30:1-123. Issue Brief Health Policy Track Serv. 2013. PMID: 24482893 No abstract available.
-
Pediatric research: coming of age in the new millennium.Am J Ther. 1999 Sep;6(5):263-82. Am J Ther. 1999. PMID: 11329108 Review.
-
The health-care nightmare: when will we awaken?Nurs Forum. 2002 Jan-Mar;37(1):33-6. doi: 10.1111/j.1744-6198.2002.tb01189.x. Nurs Forum. 2002. PMID: 12056239 Review. No abstract available.
Cited by
-
Ten common questions (and their answers) about off-label drug use.Mayo Clin Proc. 2012 Oct;87(10):982-90. doi: 10.1016/j.mayocp.2012.04.017. Epub 2012 Aug 6. Mayo Clin Proc. 2012. PMID: 22877654 Free PMC article.
-
Off-label drug use in Psychiatry Outpatient Department: A prospective study at a Tertiary Care Teaching Hospital.J Basic Clin Pharm. 2015 Mar;6(2):45-9. doi: 10.4103/0976-0105.152090. J Basic Clin Pharm. 2015. PMID: 25767363 Free PMC article.
-
Off-label use of atypical antipsychotics: cause for concern?CNS Drugs. 2012 May 1;26(5):383-90. doi: 10.2165/11632030-000000000-00000. CNS Drugs. 2012. PMID: 22448598
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
